PMV Pharma is focused on developing innovative therapies that target the p53 protein, a crucial tumor suppressor involved in maintaining DNA integrity and preventing cancer cell proliferation. Approximately half of all human cancers exhibit mutations in the p53 gene, which compromise its ability to suppress tumors. PMV Pharma leverages over 40 years of research to restore the function of mutated p53 proteins by correcting their structural geometry. This approach aims to reactivate the tumor-suppressing capabilities of p53, which is essential for halting the progression of various cancers, including breast, lung, and colorectal cancers.

The company is pioneering the development of small molecule therapeutics that selectively target and restore mutant p53 proteins, utilizing a precision oncology platform. This platform allows PMV to create a pipeline of tumor-agnostic therapies designed to address the diverse mutations found in the p53 DNA-binding domain. By focusing on the structural correction of these proteins, PMV Pharma aims to provide effective treatment options that can potentially benefit a wide range of cancer patients, thereby advancing the field of cancer therapeutics.

United States

At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

Cancer

PMV Pharma

Solid tumor/s

<p class="font_7">PC14586, a first-in-class selective p53 reactivator, is designed to stabilize the p53 Y220C mutant in which tyrosine is substituted by cysteine at amino acid 220 of the protein. This single amino acid change creates a small crevice in the p53 protein, making it thermally unstable and unable to effectively interact with DNA. Targeting this crevice with a small molecule to restore function to p53 Y220C has been proposed as a potential therapeutic strategy (Joerger&nbsp;2006; Basse 2010).</p>

PMV Pharma

Company Details